Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2
Update: 2025-05-16
Description
In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery.
This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada.
🎧 Catch up on Part 1 for insights into Claudin 18.2 testing and its role in guiding therapy decisions.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
